Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

Abstract Background Immune checkpoint inhibitors (ICIs) for solid tumors, including those targeting programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have shown impressive clinical efficacy, however, most patients do not achieve durable responses. One major the...

Full description

Bibliographic Details
Main Authors: Jared M. Newton, Aurelie Hanoteau, Hsuan-Chen Liu, Angelina Gaspero, Falguni Parikh, Robyn D. Gartrell-Corrado, Thomas D. Hart, Damya Laoui, Jo A. Van Ginderachter, Neeraja Dharmaraj, William C. Spanos, Yvonne Saenger, Simon Young, Andrew G. Sikora
Format: Article
Language:English
Published: BMJ Publishing Group 2019-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Immunotherapy
Tumor immune microenvironment
Immune checkpoint inhibitors
Programmed cell death protein-1 (PD-1)
Cytotoxic T lymphocyte associated antigen-4 (CTLA-4)
Cyclophosphamide (CTX)
Online Access:http://link.springer.com/article/10.1186/s40425-019-0698-6

Internet

http://link.springer.com/article/10.1186/s40425-019-0698-6

Similar Items